Posterior reversible encephalopathy syndrome (PRES) and myeloma.

Cerebrovascular complication Chemotherapy Myeloma Neurotoxicity Posterior reversible encephalopathy syndrome

Journal

Leukemia research reports
ISSN: 2213-0489
Titre abrégé: Leuk Res Rep
Pays: England
ID NLM: 101608906

Informations de publication

Date de publication:
2024
Historique:
received: 30 09 2023
revised: 23 12 2023
accepted: 28 12 2023
medline: 23 1 2024
pubmed: 23 1 2024
entrez: 23 1 2024
Statut: epublish

Résumé

Posterior reversible encephalopathy syndrome (PRES) has rarely been described in myeloma, but chemotherapy is a known risk factor. We report 3 patients with myeloma who developed PRES, and analyzed them with 13 published cases, mostly women. The most frequent causative agents were proteasome inhibitors and autologous stem cell transplantation. Risk factors were frequently associated: hypertension, infection or renal failure. Symptoms included headache, blurred vision, altered mental status, seizures. Most patients experienced rapid clinical recovery, without relapse even after resuming treatment. Although rare, we must remain vigilant about PRES in myeloma patients. Stricter control of blood pressure could limit its occurrence.

Identifiants

pubmed: 38260821
doi: 10.1016/j.lrr.2023.100407
pii: S2213-0489(23)00047-X
pmc: PMC10801201
doi:

Types de publication

Case Reports

Langues

eng

Pagination

100407

Informations de copyright

© 2024 The Authors. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

The authors have no conflict of interest related to this manuscript.

Auteurs

Ricardos Ghanem (R)

Centre Hospitalier Sud Francilien, Hématologie clinique, Corbeil-Essonnes, France.

Sylvie Glaisner (S)

Département d'oncologie médicale, Institut Curie, Paris, France.

Arthur Bobin (A)

Service d'Hématologie et Thérapie Cellulaire, Pôle Régional de Cancérologie, CHU de Poitiers, France.

Anne-Marie Ronchetti (AM)

Centre Hospitalier Sud Francilien, Hématologie clinique, Corbeil-Essonnes, France.

Sophie Cereja (S)

Centre Hospitalier Sud Francilien, Hématologie clinique, Corbeil-Essonnes, France.

Bertrand Joly (B)

Centre Hospitalier Sud Francilien, Hématologie clinique, Corbeil-Essonnes, France.

Célia Salanoubat (C)

Centre Hospitalier Sud Francilien, Hématologie clinique, Corbeil-Essonnes, France.

Guillemette Fouquet (G)

Centre Hospitalier Sud Francilien, Hématologie clinique, Corbeil-Essonnes, France.
Université de Paris, INSERM U1016, Institut Cochin, CNRS UMR8104, Faculté de médecine Cochin-Port Royal, Paris, France.

Classifications MeSH